NASDAQ: IRWDIronwood Pharmaceuticals Inc Stock
$0.62-0.05 (-7.46%)
Updated Jun 13, 2025
IRWD Price
$0.62
Fair Value Price
N/A
Market Cap
$100.33M
52 Week Low
$0.53
52 Week High
$7.11
P/E
-3.1x
P/B
-0.3x
P/S
0.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$317.68M
Earnings
-$32.34M
Gross Margin
100%
Operating Margin
18.21%
Profit Margin
-10.2%
Debt to Equity
-1.98
Operating Cash Flow
$79M
Beta
0.59
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
IRWD Overview
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine IRWD's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
IRWD
Ranked#31 of 59
Ranked#31 of 59
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.93 | A | |
| $5.24 | A | |
| $6.88 | A |
Be the first to know about important IRWD news, forecast changes, insider trades & much more!
IRWD News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how IRWD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
IRWD is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
IRWD is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
IRWD's Earnings (EBIT) of $57.84M... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more IRWD due diligence checks available for Premium users.
Valuation
IRWD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.1x
Industry
-23.1x
Market
31.36x
IRWD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-0.3x
Industry
2.26x
IRWD's financial health
Profit margin
Revenue
$41.1M
Net Income
-$37.4M
Profit Margin
-90.9%
IRWD's Earnings (EBIT) of $57.84M... subscribe to Premium to read more.
Interest Coverage Financials
IRWD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$327.2M
Liabilities
$661.3M
Debt to equity
-1.98
IRWD's short-term assets ($160.58M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IRWD's long-term liabilities ($613.17M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IRWD's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
IRWD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$20.0M
Investing
-$31.0k
Financing
$6.0k
IRWD's operating cash flow ($78.52M)... subscribe to Premium to read more.
Debt Coverage Financials
IRWD vs Pharmaceutical Stocks
Ironwood Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.